Denali Therapeutics stock: late Lang & Schwarz quote
Published on 11/10/2026 at 22:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline and trading focus
- Denali Therapeutics develops medicines for serious diseases affecting the brain and body.
- Its investigational pipeline spans neurodegenerative diseases, lysosomal storage disorders and other serious conditions.
Denali Therapeutics stock traded at EUR 17.80 on Lang & Schwarz at 10:18 p.m. CET on Tuesday, November 10. The quote provides a late-session reference for investors following the US biotechnology company.
Platform supports development pipeline
Denali Therapeutics says it develops and delivers medicines for people living with serious diseases affecting the brain and body. Its TransportVehicle platform is designed to help biotherapeutics cross biological barriers, including access to the brain.
The company says its investigational pipeline covers neurodegenerative diseases, lysosomal storage disorders and other serious conditions. That pipeline remains the central operating focus for investors assessing the biotechnology group's prospects.
Denali Therapeutics at a glance
- Company: Denali Therapeutics Inc.
- ISIN: US24823R1059
- Trading venue: Lang & Schwarz
- Quote: EUR 17.80 on Tuesday, November 10, 2026, at 10:18 p.m. CET
- Bid: EUR 17.73
- Ask: EUR 17.87
Denali's company website outlines the platform and the current therapeutic focus.
The S&P 500 provides the broader market context for US-listed biotechnology shares.
